Integra LifeSciences
IART
131 hedge funds and large institutions have $893M invested in Integra LifeSciences in 2013 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 50 increasing their positions, 46 reducing their positions, and 10 closing their positions.
60% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 10
13% more capital invested
Capital invested by funds: $791M → $893M (+$101M)
2% more funds holding
Funds holding: 129 → 131 (+2)
9% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 46
90% less call options, than puts
Call options by funds: $8K | Put options by funds: $81K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
Invesco
Atlanta,
Georgia
|
+$6.77M |
| 2 |
ClearBridge Investments
New York
|
+$5.56M |
| 3 |
B
Barings
Charlotte,
North Carolina
|
+$5.03M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.49M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$2.92M |
Top Sellers
| 1 |
BC
Broadfin Capital
New York
|
-$11.1M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$10.2M |
| 3 |
DM
Deerfield Management
New York
|
-$9.45M |
| 4 |
CI
Cambiar Investors
Denver,
Colorado
|
-$3.3M |
| 5 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
-$2.94M |
IART Hedge Fund Activity: Q3 2013 in Review
131 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q3 2013, worth a combined $893M — up 13% from $791M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new IART positions and 10 closed out — a net gain of 6 holders — while 50 added to existing stakes and 46 trimmed.
The largest buyer was Invesco, adding an estimated $6.77M. The largest seller was Broadfin Capital, cutting an estimated $11.1M.
- 131 institutional investors held Integra LifeSciences (IART) as of Q3 2013, up from 129 in Q2 2013.
- Funds reported $893M of Integra LifeSciences stock for Q3 2013, up 13% quarter-over-quarter.
- 16 funds opened new Integra LifeSciences positions in Q3 2013 and 10 closed out, a net change of +6 holders.
- The largest Integra LifeSciences buyer in Q3 2013 was Invesco, an estimated $6.77M added.
- The largest Integra LifeSciences seller in Q3 2013 was Broadfin Capital, an estimated $11.1M sold.
Based on aggregated 13F filings for Q3 2013.